Palbociclib is filed at FDA for treatment of HER2 advanced Breast Cancer with letrozole - Pfizer
Pfizer Inc. has announced it has completed the submission of a New Drug Application (NDA) to the FDA for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced Breast Cancer who have not received previous systemic treatment for their advanced disease.
The submission is based on the final results of PALOMA-1, a randomized, Phase II trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins